Regenesis gets $5.3M in Series C

Scottsdale, AZ-based Regenesis Biomedical announced the closing of a $5.3 million Series C equity financing in a round led by Fulcrum Equity Partners and TGap Ventures. The round also included existing investor Solstice Capital. Tom Greer of Fulcrum and Jack Ahrens of TGap will join the Regenesis board of directors.

"This funding allows us to accelerate the expansion of our sales force, and to seek expanded payer sources including Medicare coverage," said Virginia Rybski, president and CEO of Regenesis Biomedical, in a statement. "In addition we are pleased with our new partners who add to our healthcare business experience."

Privately held Regenesis focuses on developing and marketing noninvasive regenerative medicine products. Its key product is the Provant wound therapy system, which uses pulsed radio frequency energy to help reduce the pain and edema associated with post-operative, superficial soft tissues. The current funding will help in the expansion of Provant commercialization. 

- see the Regenesis release

ALSO: Mario Gabelli, one of the world's wealthiest men, put another $3.4 million into Orthovita and dropped $25 million on American Medical Systems Holdings. Item

Suggested Articles

The CE Mark for the system’s fourth iteration follows a July 2019 approval from the FDA.

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.